Icon

Xeljanz XR - (22 mg, Tablet; Extended release)

tofacitinib Pfizer
22 mg, Tablet; Extended release
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
It is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Yes
****** **** ** ***** ************** ** *** **, ****. **** ******* ** *** **, **** **** ******* ********* ******* ****** *** *****. ***** **** *** '*** *** ***********' ****** ** **** ** ***** ******** **** ***. **************** ***** * ************ ****, **** ****-** **** ******* '*** *** '*** (*** **, ****). ****** **** **************** **** ************ ** *** **** *******. * ******** **** *** *** **** ******** ** ******* **** ****************. *** ****** ******** *** **** ******** ** ***** **** (******) *** *** **** ** ****** ** *** ****.
Xeljanz XR Patent 1 Patent 2 Patent 3 Patent 4
***** ****** ******* ******* *** ********* (***** ******) *** ********* (***** ******)
**** *** ********* *** ********* ******* *** ********* (***** ******)
**************** *** ********* *** ********* **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** *** \ *** *** **, **** ******* ******** ************ ** *** **, ****
**** ** \ ** **** **, **** ******* ********* ******** ***** ***-**** ***********
**************** ** \ ** *** **, **** ******* ********* ******** *** ****** *** ****
  1. *** **, **** : ****** **** ***** ** '*** *** '***
  2. *** **, **** : **** ******* ******* ****** *** ***** **** *********** *****.
  3. *** *, **** : ** ********* ** **** *** ****** ** **** **.* ******** ****** *** ******* ** **** (*****://**************.**********.***/***-**********/********-****-****-****-************.***)
  4. *** **, **** : **** ******** ****** ********* *** **** ** ******.
  5. *** **, **** : ****** **** **** ** ****** '***.
  6. *** **, **** : ****** ********* ********** ******* **** *** **** ******* **** **.
  7. *** **, **** : **************** ******** ****** ** *** ****-** ****** **** ******* '*** *** '*** (*** **, ****)
  8. *** *, **** : *** ****** ******** ****** ** *** ****-** ****** **** ****** **'*** (*** **, ****)
  9. *** **, **** : ****** **** **************** **** ************ ** ******* '*** *** '*** (*** **, ****)
  10. *** **, **** : ****** **** *** ****** **** ************ ** **'*** (*** **, ****)
  11. *** *, **** : ****** ******** ****** ** ***** **** ** ******.
  12. *** **, **** : ****** **** ****** **** ************ ** ****** **’***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.